Indolent/Low Grade Non-Hodgkin's Lymphoma

Upcoming Educational Forum for Waldenstrom’s Macroglobulinemia Patients and Caregivers (March 9, 2017)

The 22nd Annual IWMF Educational Forum May 19-21, 2017, in Phoenix, Arizona The International Waldenstrom’s Macroglobulinemia Foundation (IWMF) is a patient-founded and patient-led, nonprofit organization... Continue Reading

Gazyva® Delays Cancer Progression as Initial Therapy in Advanced Follicular Lymphoma (January 5, 2017)

Among patients with advanced follicular lymphoma who have not received prior therapy, treatment with Gazyva® (obinutuzumab) plus chemotherapy delays cancer progression compared to the standard Rituxan®... Continue Reading

The First CAR-T Therapy Heading to the FDA (September 29, 2016)

Kite Pharma reported that its CAR-T therapy demonstrated a 39% response rate, including a 33% complete response rate, in patients with aggressive non Hodgkin lymphoma. The interim results from the phase... Continue Reading

Gazyva® Showed Superior Progression-Free Survival Compared to Rituxan® in Follicular Lymphoma (June 8, 2016)

A study in people with previously untreated follicular lymphoma, the most common type of indolent (slow-growing) non-Hodgkin’s lymphoma (iNHL) suggests that  Gazyva® (obinutuzumab) plus chemotherapy... Continue Reading

Ask the Expert: Blood Cancer Treatment Progress & What’s Next (October 7, 2015)

CancerConnect Presents: Ask the Expert: Blood Cancer Treatment Progress & What’s Next In this informative web chat, Jacqueline Barrientos, MD discusses blood cancer prevalence, evolution of blood... Continue Reading

What’s New in the Management of Lymphoma? (March 2, 2015)

What’s New in the Management of Lymphoma? Cancers that begin in cells of the lymph system are referred to as malignant lymphomas. Lymphomas range from aggressive to slow growing or indolent and can be... Continue Reading

FDA Approves New Indication for Ibrutinib in Waldenström’s Macroglobulinemia (February 24, 2015)

CancerConnect News: The US Food and Drug Administration (FDA) today expanded the approved use of Imbruvica® (ibrutinib) for patients with Waldenström’s macroglobulinemia, a rare type of B-cell lymphoma.... Continue Reading

FDA Grants Fast Track Designation to SGX301 for First-Line Treatment of Cutaneous T-Cell Lymphoma (January 19, 2015)

The U. S. Food and Drug Administration has granted Fast Track designation the synthetic hypericin (SGX301) development program for the first-line treatment of cutaneous T-cell lymphoma. Fast Track designation... Continue Reading

HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment (December 17, 2014)

CancerConnect News: HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised... Continue Reading

September Is National Blood Cancer Awareness Month (September 5, 2014)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of blood cancer educational programs for national blood cancer awareness month. As the month of September brings blood... Continue Reading

Dramatic Results Seen in Early Trials of Novel Lymphoma Treatment (July 21, 2014)

A new treatment approach for B-Cell lymphoma patients developed at the National Cancer Institute (NCI) and licensed to Kite Pharmaceuticals is showing dramatic results in pilot clinical trials. The treatment,... Continue Reading

Pidilizumab Plus Rituxan Produces High Response Rate in Relapsed Follicular Lymphoma (January 10, 2014)

Treatment with the monoclonal antibody pidilizumab plus Rituxan® (rituximab) produced a high response rate in patients with relapsed follicular lymphoma, according to the results of a study published... Continue Reading

Celiac Disease Associated with Higher Risk of Lymphoma (September 4, 2013)

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published... Continue Reading

Fractionated Zevalin Effective First-Line Treatment for Advanced Follicular Lymphoma (February 7, 2013)

Fractionated radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is an effective first-line treatment for advanced stage follicular lymphoma and delivers high response rates in patients... Continue Reading

Zevalin Effective as First-Line Treatment for Advanced Follicular Lymphoma (February 1, 2013)

Radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is safe and well tolerated and induces a high rate of clinical and molecular responses when given as first-line treatment to patients... Continue Reading

Zevalin Effective in Follicular NHL Refractory to Rituximab (January 24, 2013)

Radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is effective in patients with non-Hodgkin’s lymphoma that is refractory to treatment with Rituxan® (rituximab), according to the results... Continue Reading

Zevalin Effective in Relapsed/Refractory Follicular Lymphoma (January 11, 2013)

Radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) produces statistically and clinically significant higher overall response rates and complete response rates compared to Rituxan® (rituximab)... Continue Reading

Consolidation with Zevalin Significantly Improves Progression-Free Survival in Advanced Follicular Lymphoma (January 10, 2013)

Consolidation therapy with Zevalin® (ibritumomab tiuxetan) significantly prolongs progression-free survival and leads to high conversion rates from partial response to complete response in patients with... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS